PH12019502817A1 - Use of wx-uk1 and its prodrug, wx-671, for the treatment of non-cancerous medical conditions - Google Patents
Use of wx-uk1 and its prodrug, wx-671, for the treatment of non-cancerous medical conditionsInfo
- Publication number
- PH12019502817A1 PH12019502817A1 PH12019502817A PH12019502817A PH12019502817A1 PH 12019502817 A1 PH12019502817 A1 PH 12019502817A1 PH 12019502817 A PH12019502817 A PH 12019502817A PH 12019502817 A PH12019502817 A PH 12019502817A PH 12019502817 A1 PH12019502817 A1 PH 12019502817A1
- Authority
- PH
- Philippines
- Prior art keywords
- animal
- treatment
- pharmaceutical composition
- cancerous medical
- medical condition
- Prior art date
Links
- 229940002612 prodrug Drugs 0.000 title 1
- 239000000651 prodrug Substances 0.000 title 1
- 102000004142 Trypsin Human genes 0.000 abstract 2
- 108090000631 Trypsin Proteins 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 239000012588 trypsin Substances 0.000 abstract 2
- 208000007882 Gastritis Diseases 0.000 abstract 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
- 206010033645 Pancreatitis Diseases 0.000 abstract 1
- 229940122618 Trypsin inhibitor Drugs 0.000 abstract 1
- 101710162629 Trypsin inhibitor Proteins 0.000 abstract 1
- 230000001668 ameliorated effect Effects 0.000 abstract 1
- 239000012472 biological sample Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000013078 crystal Substances 0.000 abstract 1
- 208000010643 digestive system disease Diseases 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 208000002551 irritable bowel syndrome Diseases 0.000 abstract 1
- 239000002207 metabolite Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000000523 sample Substances 0.000 abstract 1
- 239000002753 trypsin inhibitor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96433—Serine endopeptidases (3.4.21)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/976—Trypsin; Chymotrypsin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Physiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Nutrition Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762535376P | 2017-07-21 | 2017-07-21 | |
| US201762574449P | 2017-10-19 | 2017-10-19 | |
| US201762589734P | 2017-11-22 | 2017-11-22 | |
| PCT/IB2018/000881 WO2019016595A1 (en) | 2017-07-21 | 2018-07-13 | USE OF WX-UK1 AND ITS PRODRANT WX-671 FOR THE TREATMENT OF NON-CANCER MEDICAL DISEASES |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12019502817A1 true PH12019502817A1 (en) | 2020-09-14 |
Family
ID=65014605
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH12019502817A PH12019502817A1 (en) | 2017-07-21 | 2019-12-13 | Use of wx-uk1 and its prodrug, wx-671, for the treatment of non-cancerous medical conditions |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20190022088A1 (https=) |
| EP (1) | EP3654979A4 (https=) |
| JP (1) | JP2020527582A (https=) |
| KR (1) | KR20200031567A (https=) |
| CN (1) | CN110785172A (https=) |
| AU (1) | AU2018303799A1 (https=) |
| CA (1) | CA3070037A1 (https=) |
| CL (1) | CL2020000096A1 (https=) |
| IL (1) | IL271878A (https=) |
| PH (1) | PH12019502817A1 (https=) |
| RU (1) | RU2020107706A (https=) |
| SG (1) | SG11201912043QA (https=) |
| WO (1) | WO2019016595A1 (https=) |
| ZA (1) | ZA201908545B (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111494602B (zh) * | 2020-04-14 | 2023-06-02 | 广州领晟医疗科技有限公司 | 一种治疗急性胰腺炎的组合物及其用途 |
| CN111494392A (zh) * | 2020-04-14 | 2020-08-07 | 广州领晟医疗科技有限公司 | 一种用于治疗急性肺损伤的组合物及其应用 |
| CN113559100B (zh) * | 2021-08-30 | 2023-01-17 | 广州领晟医疗科技有限公司 | 一种治疗肺损伤的组合物及其应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5534498A (en) * | 1992-01-30 | 1996-07-09 | Corvas International, Inc. | Trypsin inhibitors |
| US7342018B2 (en) * | 1998-07-20 | 2008-03-11 | Wilex Ag | Urokinase inhibitors and uses thereof |
| AU2003206945A1 (en) * | 2002-02-22 | 2003-09-09 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Use of proteinase inhibitors in the treatment of autoimmune diseases |
| DE10323898A1 (de) * | 2003-05-26 | 2004-12-23 | Wilex Ag | Hydroxyamidin- und Hydroxyguanidin-Verbindungen als Urokinase-Hemmstoffe |
| EP3309556B1 (en) * | 2009-06-25 | 2020-04-08 | Prometheus Biosciences, Inc. | Methods for diagnosing irritable bowel syndrome |
-
2018
- 2018-07-13 WO PCT/IB2018/000881 patent/WO2019016595A1/en not_active Ceased
- 2018-07-13 EP EP18835233.0A patent/EP3654979A4/en not_active Withdrawn
- 2018-07-13 SG SG11201912043QA patent/SG11201912043QA/en unknown
- 2018-07-13 KR KR1020197037453A patent/KR20200031567A/ko not_active Ceased
- 2018-07-13 CA CA3070037A patent/CA3070037A1/en not_active Abandoned
- 2018-07-13 US US16/034,815 patent/US20190022088A1/en not_active Abandoned
- 2018-07-13 RU RU2020107706A patent/RU2020107706A/ru not_active Application Discontinuation
- 2018-07-13 JP JP2020502586A patent/JP2020527582A/ja active Pending
- 2018-07-13 CN CN201880042082.2A patent/CN110785172A/zh active Pending
- 2018-07-13 AU AU2018303799A patent/AU2018303799A1/en not_active Abandoned
-
2019
- 2019-12-13 PH PH12019502817A patent/PH12019502817A1/en unknown
- 2019-12-20 ZA ZA2019/08545A patent/ZA201908545B/en unknown
-
2020
- 2020-01-07 IL IL271878A patent/IL271878A/en unknown
- 2020-01-13 CL CL2020000096A patent/CL2020000096A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SG11201912043QA (en) | 2020-02-27 |
| EP3654979A4 (en) | 2021-04-14 |
| RU2020107706A (ru) | 2021-08-23 |
| CN110785172A (zh) | 2020-02-11 |
| JP2020527582A (ja) | 2020-09-10 |
| CL2020000096A1 (es) | 2020-08-28 |
| CA3070037A1 (en) | 2019-01-24 |
| RU2020107706A3 (https=) | 2021-10-15 |
| US20190022088A1 (en) | 2019-01-24 |
| AU2018303799A1 (en) | 2019-12-19 |
| IL271878A (en) | 2020-02-27 |
| ZA201908545B (en) | 2021-02-24 |
| WO2019016595A1 (en) | 2019-01-24 |
| EP3654979A1 (en) | 2020-05-27 |
| KR20200031567A (ko) | 2020-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019502817A1 (en) | Use of wx-uk1 and its prodrug, wx-671, for the treatment of non-cancerous medical conditions | |
| MX384721B (es) | Tratamiento del cáncer usando combinaciones de inhibidores de erk y raf. | |
| MA33076B1 (fr) | Utilisation d'un inhibiteur de la gamma-secretase pour le traitement du cancer | |
| MX391850B (es) | Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington | |
| EA201691803A1 (ru) | Ингибиторы калликреина плазмы человека | |
| NZ619076A (en) | Isoxazolines as inhibitors of fatty acid amide hydrolase | |
| SG10201810401RA (en) | Pharmaceutical combinations for treating cancer | |
| PH12017500444A1 (en) | Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia | |
| AR105712A1 (es) | Composiciones de insulina de rápida acción | |
| PH12013502677A1 (en) | Benzylamine derivatives as inhibitors of plasma kallikrein | |
| EA201800499A1 (ru) | Ингибитор тирозинкиназы для лечения амиотрофного латерального склероза, композиция, лекарственное средство, набор | |
| EA201200472A1 (ru) | Сульфонамиды в качестве ингибиторов белков семейства bcl-2, предназначенные для лечения рака | |
| BR112017017275A2 (pt) | composto, composição farmacêutica, método para o tratamento e uso do composto | |
| NO20072631L (no) | Kreftbehandlingsmetode | |
| EA201401231A1 (ru) | Фармацевтические комбинации, предназначенные для лечения метаболических нарушений | |
| MD20140044A2 (ro) | 2-Tiopirimidinone şi utilizarea lor pentru tratamentul afecţiunilor cardiovasculare | |
| EA201591541A1 (ru) | Ингибиторы бета-секретазы 1 (bace 1) | |
| EA201692481A1 (ru) | Комбинация, содержащая глюкокортикоид и edo-s101 | |
| PH12021550713A1 (en) | Medicament for the treatment of chronic cough | |
| ATE555116T1 (de) | Ahcy-hydrolasehemmer zur behandlung von hyperhomocysteinämie | |
| EA201591773A1 (ru) | Макроциклические ингибиторы rip2-киназы | |
| EA201890862A1 (ru) | Ингибиторы плазменного калликреина человека | |
| UA86441C2 (ru) | (2-гидроксиэтил)триметиламмония тиоктат (холина тиоктат), имеющий гепатопротекторное, гипоаммониемическое и детоксицирующее действие, способ его получения, фармацевтическая композиция на его основе | |
| JP2016199578A5 (https=) | ||
| PH12019500618A1 (en) | Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease |